Prostaglandin E2 EP receptors as therapeutic targets in breast cancer

@article{Reader2011ProstaglandinEE,
  title={Prostaglandin E2 EP receptors as therapeutic targets in breast cancer},
  author={Jocelyn Christine Reader and Dawn M Holt and Amy P. Fulton},
  journal={Cancer and Metastasis Reviews},
  year={2011},
  volume={30},
  pages={449-463}
}
Prostaglandins are lipid compounds that mediate many physiological effects. Prostaglandin E2 (PGE2) is the most abundant prostanoid in the human body, and synthesis of PGE2 is driven by cyclooxygenase enzymes including COX-2. Both elevated expression of COX-2 and increased PGE2 levels have been associated with many cancers including breast cancer. PGE2 exerts its effect by binding to the E series of prostaglandin receptors (EP) which are G protein-coupled receptors. Four EP receptor subtypes… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 50 CITATIONS

EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer

Anna Semmlinger, Viktoria von Schoenfeldt, +14 authors Nina Ditsch
  • BMC Cancer
  • 2018
VIEW 9 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2011
2019

CITATION STATISTICS

  • 2 Highly Influenced Citations

  • Averaged 6 Citations per year over the last 3 years

  • 9% Increase in citations per year in 2018 over 2017

References

Publications referenced by this paper.
SHOWING 1-10 OF 153 REFERENCES

Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2010
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Cyclooxygenases, prostanoids, and tumor progression

  • Cancer and Metastasis Reviews
  • 2007
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…